Go Back This article was viewed 158 times

Review Article


Circulating tumor cells in breast cancer

Akhil JainMoushumi SuryavanshiUllas BatraPankaj GoyalDinesh Doval
Departments of Medical Oncology1Consultant, Center for Molecular Diagnostics & Cell Biology, 2Department of Medical Oncology & Research, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India, 
Corresponding Author:

Akhil Jain

Departments of Medical Oncology, Center for Molecular Diagnostics & Cell Biology, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India
E-mail: drakhiljain17@gmail.com

Corresponding Author:

Akhil Jain

Departments of Medical Oncology, Center for Molecular Diagnostics & Cell Biology, Rajiv Gandhi Cancer Institute & Research Centre, NewDelhi, India
E-mail: drakhiljain17@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20170052

ABSTRACT


Breast cancer is a heterogeneous disease. Liquid biopsy is a novel diagnostic tool and may provide answers to many questions related to unevenness in prognosis and ultimate outcome. Different technologies for CTC isolation, enrichment, detection, and characterization are under evaluation. Various clinical trials and meta-analysis have been conducted to define the role of CTC in early and metastatic breast cancer. CTCs are superior to other serum markers for prognostication. Their role as predictive marker remains elusive.
Keywords: Circulating tumor cells, Early breast cancer, Metastatic breast cancer, Liquid biopsy

Cited in 1 Document

  1. Mahlet Fasil Abate, Shasha Jia, Metages Gashaw Ahmed, Xingrui Li, Li Lin, Xiaoqian Chen, Zhi Zhu and Chaoyong Yang (2019) Visual Quantitative Detection of Circulating Tumor Cells with Singleā€Cell Sensitivity Using a Portable Microfluidic Device. Small 15(14):1804890. doi: 10.1002/smll.201804890

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.